1198221-21-4
1198221-21-4 structure
- Name: TAS-114
- Chemical Name: TAS-114
- CAS Number: 1198221-21-4
- Molecular Formula: C21H29N3O6S
- Molecular Weight: 451.54
- Catalog: Research Areas Cancer
- Create Date: 2019-06-01 16:25:21
- Modify Date: 2025-08-25 14:19:03
-
TAS-114 is a dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine[1].
| Name | TAS-114 |
|---|
| Description | TAS-114 is a dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine[1]. |
|---|---|
| Related Catalog | |
| Target |
dUTPase, DPD |
| In Vitro | TAS-114 (1-10 μM; 72 hours) increases the cytotoxicity of 5-Fluorouracil (5-FU) and 5-FU,2′-deoxy-5-fluorouridine (FdUrd) against various cancer cell lines in dose-dependent manner[1]. Cell Cytotoxicity Assay[1] Cell Line: HeLa, NUGC-4, NCI-H441, HT-29, CFPAC-1, and MCF-7 cell lines Concentration: 72 hours Incubation Time: 1 μM, 3 μM, and 10 μM Result: Clearly increased the cytotoxicity of FdUrd and 5-FU against various cancer cell lines in dose-dependent manner. |
| In Vivo | TAS-114 (37.5-1,200 mg/kg/day; orally; 1-14 days) increases the antitumor activity of 5-FU when co-administers with Capecitabine (539 mg/kg/day) in mice[1]. Animal Model: BALB/c nude mice with MX-1 human breast cancer xenografts[1] Dosage: 37.5 to 1,200 mg/kg/day Administration: Orally; daily; 1-14 days Result: Decreased the tolerable doses of Capecitabine (539 mg/kg/day) in a dose-dependent manner in mice. |
| References |
| Molecular Formula | C21H29N3O6S |
|---|---|
| Molecular Weight | 451.54 |